Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07229716

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

Status
Not Yet Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGHRS-9813 CapsuleHRS-9813 capsule, specified dose on specified days.
DRUGNintedanib Soft CapsulesNintedanib soft capsules, specified dose on specified days.
DRUGPirfenidone TabletsPirfenidone tablets, specified dose on specified days.

Timeline

Start date
2025-11-01
Primary completion
2026-04-01
Completion
2026-04-01
First posted
2025-11-17
Last updated
2025-11-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07229716. Inclusion in this directory is not an endorsement.